NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.250
+0.130 (11.61%)
At close: Aug 13, 2025, 4:00 PM
1.250
0.00 (0.00%)
After-hours: Aug 13, 2025, 6:59 PM EDT
NeuroSense Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for NeuroSense Therapeutics stock has a target of 14, which predicts a 1,020.00% increase from the current stock price of 1.25.
Price Target: $14.00 (+1,020.00%)
Analyst Consensus: Buy
* Price targets were last updated on Jul 10, 2025.
Analyst Ratings
The average analyst rating for NeuroSense Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,020.00% | Jul 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +1,020.00% | May 12, 2025 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 16, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $7.5 | Strong Buy | Initiates | $7.5 | +500.00% | Jul 17, 2023 |
| Maxim Group | Maxim Group | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +460.00% | Jan 7, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
728.28K
EPS This Year
-0.51
from -0.55
EPS Next Year
-0.32
from -0.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 2.2M | 6.9M | ||
| Avg | n/a | 728,280 | 3.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 845.2% | ||
| Avg | - | - | 359.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.34 | -0.16 | -0.21 | ||
| Avg | -0.51 | -0.32 | -0.21 | ||
| Low | -0.59 | -0.54 | -0.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.